pyridinoline has been researched along with Endometrioma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amama, EA; Minaguchi, H; Taga, M | 1 |
| Freundl, G; Gnoth, CH; Godehardt, E; Gödtke, K; Kienle, E | 1 |
| Kiesel, L; Parviz, M; Runnebaum, B; Seibel, MJ; Sillem, M; Ulrich, U; von Holst, T; Woitge, HW; Ziegler, R | 1 |
2 trial(s) available for pyridinoline and Endometrioma
| Article | Year |
|---|---|
Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists.
Topics: Amino Acids; Bone Density; Calcium; Desogestrel; Double-Blind Method; Endometriosis; Ethinyl Estradiol; Female; Humans; Leuprolide; Pelvic Pain; Placebos; Prospective Studies | 1999 |
Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin.
Topics: Adult; Alkaline Phosphatase; Amino Acids; Bone and Bones; Bone Density; Bone Remodeling; Double-Blind Method; Endometriosis; Female; Goserelin; Humans; Kinetics; Medrogestone; Osteocalcin; Osteoporosis; Placebos; Premenopause; Progesterone Congeners | 1999 |
1 other study(ies) available for pyridinoline and Endometrioma
| Article | Year |
|---|---|
The effect of gonadotropin-releasing hormone agonist on type I collagen C-telopeptide and N-telopeptide: the predictive value of biochemical markers of bone turnover.
Topics: Adult; Alkaline Phosphatase; Amino Acids; Antineoplastic Agents, Hormonal; Biomarkers; Bone Remodeling; Buserelin; Collagen; Collagen Type I; Endometriosis; Estradiol; Female; Goserelin; Humans; Hydroxyproline; Leiomyoma; Osteocalcin; Peptides; Retrospective Studies | 1998 |